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Chern-En Chiang, MD, PHD,* Dan M. Roden, MD, FACC†
Taipei, Taiwan and Nashville, Tennessee
It is becoming clear that mutations in the KVLQT1, human “ether-a-go-go” related gene,
cardiac voltage-dependent sodium channel gene, minK and MiRP1 genes, respectively, are
responsible for the LQT1, LQT2, LQT3, LQT5 and LQT6 variants of the Romano-Ward
syndrome, characterized by autosomal dominant transmission and no deafness. The much
rarer Jervell-Lange-Nielsen syndrome (with marked QT prolongation and sensorineural
deafness) arises when a child inherits mutant KVLQT1 or minK alleles from both parents.
In addition, some families are not linked to the known genetic loci. Cardiac voltage-
dependent sodium channel gene encodes the cardiac sodium channel, and long QT syndrome
(LQTS) mutations prolong action potentials by increasing inward plateau sodium current.
The other mutations cause a decrease in net repolarizing current by reducing potassium
currents through “dominant negative” or “loss of function” mechanisms. Polymorphic
ventricular tachycardia (torsade de pointes) is thought to be initiated by early after-
depolarizations in the Purkinje system and maintained by reentry in the myocardium. Clinical
presentations vary with the specific gene affected and the specific mutation. Nevertheless,
patients with identical mutations can also present differently, and some patients with LQTS
mutations may have no manifest baseline phenotype. The question of whether the latter
situation is one of high risk for administration of QT prolonging drugs or during myocardial
ischemia is under active investigation. More generally, the identification of LQTS genes has
provided tremendous new insights for our understanding of normal cardiac electrophysiology
and its perturbation in a wide range of conditions associated with sudden death. It seems
likely that the approach of applying information from the genetics of uncommon congenital
syndromes to the study of common acquired diseases will be an increasingly important one in
the next millennium. (J Am Coll Cardiol 2000;36:1–12) © 2000 by the American College
of Cardiology
The Long QT Syndrome (LQTS) is an uncommon and
fascinating disorder. Jervell and Lange-Nielsen (1) reported
the first case with prolonged QT interval, congenital deaf-
ness and sudden death in children; they speculated that
death was due to asystole. Since that initial report, LQTS
has drawn tremendous interest from clinicians and basic
scientists. An initial mechanism proposed was the “sympa-
thetic imbalance” theory, while later workers suggested the
concept that a defect in a specific membrane ionic channel
would prove responsible. The identification of mutations in
genes encoding ionic channel proteins supports the latter
view. The identification of LQTS genes and developing
correlations between specific mutations and clinical presen-
tations not only will contribute to improved therapy for
patients with this intriguing disorder but will also provide a
good model for further studies of the way that specific
genetic abnormalities can alter cardiac electrophysiology
and, eventually, how they may be treated.
BACKGROUND
Jervell and Lange-Nielsen (1) provided the first formal
description of the disease in 1957 in a family with four
children who suffered from congenital deafness, syncope
and QT prolongation in electrocardiogram (ECG). Three
children died suddenly; the parents, who were not consan-
guineous, and two other children had normal QT interval
and hearing and led a normal life. In the early 1960s,
Romano et al. (2) and Ward (3) independently described a
similar disease entity but without deafness. Thus, the
Romano-Ward (RW) syndrome is an autosomal dominant
disorder without congenital deafness while Jervell-Lange-
Nielsen (JLN) syndrome has been viewed as an autosomal
recessive disease with congenital deafness.
Yanowitz et al. (4) found that the QT interval could be
prolonged by right stellectomy or left stellate ganglion
stimulation. Subsequently, Schwartz et al. (5) were able to
induce T wave alternans (often seen in LQTS patients) by
left stellate ganglion stimulation. They further successfully
treated a medically refractory young patient by left stellec-
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tomy. It was at that time that “sympathetic imbalance”
theory prevailed: the syncopal episodes were thought to be
due to sudden sympathetic discharges from the left stellate
ganglion.
The first comprehensive report on the beneficial effects of
beta-adrenergic blocking agents appeared in 1975 (6) and
was further substantiated a decade later (7). The reported
10-year mortality rate was reduced from 71% in untreated
patients to 6% by beta-blockers or left cardiac sympathetic
denervation.
In 1979, Cramptom et al. (8) initiated the International
Registry for LQTS, which, in the intervening years, has
enrolled over 2,000 families. As described below, the Reg-
istry is providing a rich source of clinical and family data,
which can now be interpreted in a modern genetic context.
In 1991, Keating et al. (9) reported very tight linkage to
the Harvey ras-1 locus on the short arm of chromosome 11
(11p15.5) in a large LQTS kindred. Harvey ras-1 was ruled
out as the disease gene (10), and the actual gene at this locus
(LQT1) remained unidentified for another five years. In the
nine months between March 1995 and January 1996, three
LQTS genes were identified (11–13), and two further genes
have been implicated since (14,15). Families unlinked to any
known locus have been reported (16), and mechanisms
underlying the JLN syndrome have been identified (17–19).
Importantly, clinical differences among affected patients
(depending on the specific gene and perhaps the specific
mutations) have now been observed (20–23), and genotype-
specific therapy has now been proposed (24,25). As well, it
is becoming clear that the clinical manifestations of LQTS
vary among individuals carrying the same mutations (26),
with some affected patients even displaying normal QT
intervals (27).
INCIDENCE
The incidence of RW syndrome is unknown, estimated to
be about one gene carrier in 10,000 population (20,28). But
increasing identification of apparently asymptomatic gene
carriers with normal QT intervals may make this an under-
estimate. The JLN syndrome is much rarer. Fraser et al.
(29) estimated that the prevalence of JLN syndrome in
children aged 4 to 15 years in England, Wales and Ireland
at between 1.6 and 6 per million.
MOLECULAR BIOLOGY (TABLE 1)
Keating et al. (9), using genome-wide linkage analysis,
mapped the first gene for LQTS to chromosome 11p15.5 in
a single large kindred. However, LQT locus heterogeneity
was subsequently demonstrated (30,31).
KVLQT1 (KCNQ1). In 1996, Wang et al. (13), using
positional cloning, found the chromosome 11-linked LQTS
gene (LQT1) to be KVLQT1 at 11p15.5. KVLQT1 is
strongly expressed in the heart and encodes a protein with
structural features of a voltage-gated potassium channel.
Multiple mutations, giving rise to amino acid substitutions
or truncated proteins, have now been described in
KVLQT1-linked LQTS (32–43) (Fig. 1).
KVLQT1 has the six membrane spanning segment to-
pology typical of a voltage-gated potassium channel (13),
and protein subunits are thought to co-assemble with minK
(see below) to form the channel responsible for slowly
activating component of delayed rectifier potassium current
(IKs). KVLQT1 is expressed not only in the heart but also
in other human tissues such as pancreas, kidney, placenta
and lung but not in liver, skeletal muscle or brain (13). It has
also been shown by in situ hybridization that KVLQT1 is
expressed in the stria vascularis of mouse inner ear (17),
which is important in understanding the deafness seen in
JLN syndrome.
In individuals with LQT1, normal and mutant KVLQT1
alleles are coexpressed in myocytes. In some cases, the
mutant form of KVLQT1 interferes with the function of
the normal wild-type form through a dominant-negative
(“poison pill”) mechanism. In other cases, the mutant
protein shows no function. In either case, IKs is decreased,
resulting in prolongation of cardiac repolarization and an
increased risk of arrhythmias (34). Recently, recessive forms
Abbreviations and Acronyms
ECG 5 electrocardiogram
HERG 5 human “ether-a-go-go” related gene
IKr 5 rapidly activating component of delayed
rectifier potassium current
IKs 5 slowly activating component of delayed
rectifier potassium current
JLN 5 Jervell-Lange-Nielsen
LQTS 5 long QT syndrome
MiRP1 5 minK related peptide 1
QTc 5 corrected QT interval
RW 5 Romano-Ward
SCN5A 5 cardiac voltage-dependent sodium channel
gene
Table 1. Current Genetic Information in LQTS
Chromosome
Locus Gene Current
Autosomal dominant (Romano-Ward)
LQT1 11p15.5 KVLQT1 (KCNQ1) 2IKs
LQT2 7q35–36 HERG 2IKr
LQT3 3p21–24 SCN5A 1INa
LQT4 4q25–27 Unknown Unknown
LQT5 21q22.1–22.2 MinK (KCNE1) 2IKs
LQT6 21q22.1–22.2 MiRP1 (KCNE2) 2IKr
LQT7 Unknown Unknown Unknown
Autosomal recessive (Jervell-Lange-Nielsen)
JLN1 11p15.5 KVLQT1 (KCNQ1) +IKs
JLN2 21q22.1–22.2 MinK (KCNE1) +IKs
JLN3 Unknown Unknown Unknown
HERG 5 human “ether-a-go-go” related gene; IKr 5 rapidly activating component
of delayed rectifier potassium current; IKs 5 slowly activating component of delayed
rectifier potassium current; INa 5 sodium current; JLN 5 Jervell-Lange-Nielsen
syndrome; MiRP1 5 minK related peptide 1; SCN5A 5 cardiac voltage-dependent
sodium channel gene.
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of RW syndrome without deafness have been described in
patients homozygous for KVLQT1 mutations (45,46).
Since these parents, like JLN parents, are heterozygous for
a KVLQT1 mutation but have a normal QT interval, it is
thought that not all KVLQT1 mutations are clinically
manifest or there is variable penetrance. Thus, phenotypi-
cally mild (subclinical) mutations in LQTS genes may be
present among the general population, and it has been
suggested that these patients may be predisposed to drug- or
stress-induced arrhythmias (33,45).
In 1997, Neyroud et al. (17) linked JLN to chromosome
11p15.5 by analyzing four consanguineous families. They
then identified a homozygous deletion-insertion event in
the C-terminal domain of KVLQT1 in three affected
children of two families. Thereafter, Splawski et al. (18) also
described a patient homozygous for a KVLQT1 mutation
from a family with an autosomal dominant LQTS. This
patient had marked corrected QT interval (QTc) prolonga-
tion and congenital deafness while the parents were pheno-
typically normal. Severe QT prolongation and deafness
presumably reflect marked decreases in IKs channels. The
finding that KVLQT1 is expressed in the stria vascularis of
mouse inner ear provides further evidence that KVLQT1
plays a pivotal role in normal hearing, probably through
maintaining the endolymph homeostasis (17). Thus, it is
now accepted that homozygous mutations of KVLQT1
cause JLN syndrome (JLN1) (19,47,48) (Fig. 1), and
consanguinity is frequent in these families. The deafness
requires the presence of two mutant alleles. Jervell-Lange-
Nielsen syndrome patients are also thought to be highly
susceptible to arrhythmias although even a single mutant
allele (as in the parents) appears to increase arrhythmia risk;
thus, arrhythmia risk seems dependent on “gene dosage.”
Human “ether-a-go-go” related gene (HERG). The
LQT2 locus was mapped in affected families to 7q35–36
(49), and the gene was then identified by a candidate gene
approach, that is, screening for genes at the identified locus
yielded mutations in affected individuals. The LQT2 dis-
ease gene is HERG, which also encodes a potassium
channel (50). Curran et al. (12) identified six LQTS-
associated mutations in HERG and concluded that the
latter is the gene responsible for chromosome 7-linked
LQTS (LQT2). As with KVLQT1, multiple mutations in
HERG have been identified (35,51–59) (Fig. 1).
The HERG is highly expressed in the heart (12), and,
like other potassium channels, the encoded protein has six
transmembrane segments. The HERG encodes the major
subunit of the rapidly activating component of the delayed
rectifier potassium current (IKr) (50). This outward current
is the major contributor to the rapid repolarization of phase
3 of the action potential recorded from human myocytes. As
with KVLQT1, mutations of the gene cause loss-of-
function or dominant-negative IKr suppression to decrease
the repolarizing currents (60). Defects in biosynthetic pro-
cessing of mutant HERG channel protein have also been
reported (56,61). In vitro minK has been reported to be able
to co-assemble with HERG to modulate the amplitude of
the repolarizing current (62). More recently, minK-related
peptide 1 (MiRP1) has been identified as a protein partner
for HERG, and MiRP1 mutations have been implicated in
drug-associated LQTS (15) (see below). The IKr is also the
primary molecular target for methanesulfonanilide (63) and
Figure 1. Mutations causing the long QT syndrome in the sodium channel protein (SCN5A, top) and potassium channel protein complexes IKs, encoded
by KvLQT1 and minK and IKr, encoded by HERG and MiRP1. The arrows show the locations of the pores through which sodium or potassium ions
permeate. The unfilled symbols show the location of mutations reported in the autosomal dominant Romano-Ward form of the syndrome and the gray
symbols are those associated with the autosomal recessive form (Jervell-Lange-Nielsen). Point mutations are shown by circles, insertion/deletion events
or splice events that leave the open reading frame intact are shown by squares and truncations are shown by triangles (adapted from reference [44] with
permission). HERG 5 human “ether-a-go-go” related gene; MiRP1 5 minK related peptide 1; SCN5A 5 cardiac voltage-dependent sodium channel
gene.
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most other blocking drugs known to cause torsade de
pointes (64), thus linking the congenital and acquired
syndromes. A recent report has described a child homozy-
gous for a HERG mutation, who presented with marked
QT prolongation and arrhythmias but no deafness at birth
(59).
Cardiac voltage-dependent sodium channel gene
(SCN5A). The candidate gene approach was undertaken
by Jiang et al. (49) and Wang et al. (11) who discovered that
the gene responsible for chromosome 3-linked LQTS
(LQT3) is the cardiac sodium channel gene SCN5A (3p21–
24). The initially described mutation was an intragenic
deletion of nine nucleotides (three amino acids) in a region
that is important for channel inactivation. Thereafter, other
investigators (65–70) reported other mutations, further
confirming SCN5A to be the gene for LQT3 (Fig. 1).
Cardiac voltage-dependent sodium channel gene encodes
a protein with four homologous domains (DI–DIV), each of
which contains six transmembrane segments (S1–S6) (71).
Thus, unlike the case with potassium channels, expression
of a single sodium channel protein is sufficient to recapitu-
late sodium current. It is highly expressed in human heart,
but not in brain, liver or skeletal muscle (where other genes
are required for sodium current) (72). Whereas the
KVLQT1- and HERG-encoded gene defects represent a
loss of channel function, the SCN5A-encoded defects result
in a “gain of function” abnormality. The LQT3 mutations
produce a persistent noninactivating, mexiletine- and
tetrodotoxin-sensitive sodium inward current in the plateau
phase of cardiac action potential through several mecha-
nisms (65–67,69,73). Another recently reported mechanism
was that a point mutation in the alpha-subunit of the
human sodium channel induced a change in alpha- and
beta-interaction with resulting change in inactivation of the
heteromeric channels (66). The end result is a prolongation
of cardiac action potential and an increased risk of torsade
de pointes. One large kindred with a single SCN5A
mutation causing LQT3 and the Brugada syndrome has also
been reported (74).
MinK (KCNE1). MinK was first cloned by Takumi et al.
(75) from rat kidney cDNA library and mapped to chro-
mosome 21q22.1–q22.2 (76). The cloned cDNA encodes a
membrane protein that consists of 130 amino acids with a
single putative transmembrane domain. It can induce a
slowly activating, voltage-dependent potassium current by
co-assembling with oocyte-endogenous KVLQT1 tran-
scripts in Xenopus oocytes (75). It is now generally accepted
that minK coassembles with KVLQT1 to form IKs (77,78).
Splawski et al. (14) defined minK missense mutations in
affected members of two LQT families. Both mutations
(S74L, D76N) reduced IKs by shifting the voltage depen-
dence of activation and accelerating channel deactivation. It
has also been shown that mutant IKs channels formed with
D76N and S74L minK subunits have lower unitary currents
and diminished open probabilities (79). Thus, these func-
tional studies support the idea that minK represents a fifth
LQTS locus (LQT5) (80) (Fig. 1). Interpretation of the
clinical manifestations of LQT5 may be complicated by
differing effects of minK mutations on KVLQT1 and
HERG (81). The functional consequences of these muta-
tions would be delayed cardiac repolarization and an in-
creased risk of arrhythmia.
As with KVLQT1, homozygotes for minK mutations
have been identified among JLN patients. Schulze-Bahr et
al. (19) studied a Lebanese family with JLN syndrome, in
which three of six children had prolonged QTc intervals and
congenital bilateral deafness or deaf-mutism (19). Two of
the three had suffered from recurrent syncope since early
childhood. Both parents and the three other children
showed normal hearing and normal QTc. In this family,
mutations in minK (KCNE1), with one mutant allele from
the father and a different mutant allele from the mother,
were found in all affected children; this is termed compound
heterozygosity. Unaffected individuals had only one mutant
allele. One mutation, Asp76Asn mutation, corresponded to
a mutation in rat minK (Asp77Asn), which showed a severe
reduction of the IKs-channel activity upon expression in
Xenopus oocytes (82). Duggal et al. (80) found the same
mutation (Asp76Asn) in minK in a patient with JLN
syndrome. The proband’s mother and half-sister were both
heterozygous for this mutation. Interestingly, both these
family members had prolonged QTc intervals, thereby
showing that not all JLN “carriers” have a normal pheno-
type. Like KVLQT1, the minK gene is expressed in the
inner ear. Genetically modified mice in which the minK
locus is disrupted (minK –/–) exhibit a movement disorder
(shaker/waltzer behavior) (83) typical of an inner ear defect.
In the inner ear of knockout animals, hair cells degenerate,
and the strial marginal cells and the vestibular dark cells are
unable to generate an equivalent short circuit current in
vitro, indicating a lack of transepithelial potassium secre-
tion. The mice also have blunted QT adaptation to heart
rate variation, which may reflect greater susceptibility to
arrhythmias (83). Kupershmidt et al. (84) have observed a
similar movement disorder in their minK-knockout/LacZ-
knockin mice. These findings provide convincing evidence
that minK is one of the JLN genes (JLN2) (Fig. 1).
MiRP1. Recently, a novel potassium channel gene encod-
ing MiRP1 has been cloned (15). This small membrane
protein is thought to assemble with HERG to alter its
function. Unlike channels formed only with HERG, mixed
complexes resemble native cardiac IKr channels in their
gating, unitary conductance, regulation by potassium and
distinctive biphasic inhibition by the class III antiarrhyth-
mic E-4031. Three missense mutations associated with
LQTS and ventricular fibrillation were identified in
MiRP1. Mutants form channels that open slowly and close
rapidly, thereby diminishing potassium currents. These
findings support the idea that MiRP1 is one of the LQT
genes (LQT6) (Fig. 1). Although MiRP1 mutations have
been described in drug-associated LQTS, and co-expression
of HERG with MiRP1 does appear to modulate drug
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sensitivity of IKr, the exact role of MiRP1 expression in the
heart is still an open question, especially considering that it
has been difficult to detect in cardiac tissue.
Unidentified genes. The LQT4 locus has been linked to
chromosome 4q25-27 in a 65-member family (16). The
responsible gene has not yet been found. Patients in this
family are characterized by severe bradycardia, a bizarre T
wave and atrial fibrillation.
At most, 50% to 75% of families with RW syndrome are
linked to LQT1 through LQT6 genotypes. Marks et al.
(85) identified three boys with LQTS, atrioventricular block
and simple syndactyly. The QT intervals were extremely
prolonged (QTc . 600 ms). Two of the three children died
suddenly despite treatment with beta-adrenergic blocking
agents and permanent pacing. Syndactyly and LQTS have
also been reported in women patients (86). The responsible
genes for these patients and those in whom the RW
syndrome has not been linked remain to be determined.
There are still some patients with JLN syndrome in
whom disease genes have not been found (87), indicating
further genetic heterogeneity in JLN syndrome, as in RW
syndrome.
SYMPTOMATOLOGY
Most data on clinical presentations were gathered before it
was understood that multiple mutations, on multiple genes,
can cause LQTS and that patients may display highly
variable phenotypes including even no phenotype. Most
clinical data relate to LQT1 and LQT2, the most common
subtypes, and may not apply to rarer forms. It has been
stated that no more than 60% of patients are symptomatic
(20,28). Syncope, seizure-like activity and cardiac arrest are
the common clinical presentations. Eighty-five percent of
events are related to physical activity and emotional stress.
Sometimes auditory stimuli, such as a telephone ringing or
an alarm clock sounding, will trigger the syncopal episodes,
especially in patients with LQT2 (23). A higher incidence
of syncope was found to occur during menstruation (88) and
in the postpartum period (89). Fifteen percent of the
symptoms occurred during rest or sleep, and this is thought
to occur more commonly in LQT3 patients (20,21). Thirty
percent of patients have no family history; these cases have
de novo mutations or reflect reduced penetrance. In LQT1
(the most common), the risk of cardiac events is higher in
men until puberty and higher in women during adulthood
(90). These genotype-specific clinical features are shown in
Table 2.
ECG PATTERNS
QT prolongation. A widely accepted method for correct-
ing QT interval for rate is Bazett’s formula (91): QTc 5
QT 4 (RR)1/2. Lead II is generally the best single lead for
measuring QT interval (28) because the T wave ending is
usually discrete and the QT interval obtained from lead II
has a good correlation with the maximal QT measured from
the 12-lead ECG. A QTc interval longer than 440 ms has
been considered prolonged. However, data from the Inter-
national Registry for LQTS show that 68 (5%) of 1,345
family members who have a QTc , 440 ms had a cardiac
arrest (88), suggesting affected patients may (sometimes or
always) have normal QT intervals. Garson et al. (92)
similarly reported that 6% of 287 patients with LQTS had
a normal QTc interval. An analysis of 199 members from
LQT1-genotyped families demonstrated that, with a QTc
cutoff value of 440 ms, 11% of family members were
misclassified (20). No affected gene carriers had a QTc of
410 ms or less, and no normal persons had a QTc of 470 ms
or more (men) or 480 ms or more (women) (20). If a QTc
of 460 ms was used as a cutoff point, the positive predictive
value was 92%, and the negative predictive value was 94%
(28). Since 6% of gene carriers have a first normal QTc, and
QTc can vary on repeated tracings, repeat ECGs are
indicated to identify disease carriers if the suspicion is high.
Eventually, genotyping will be available to address molecu-
lar diagnosis.
During an exercise test, an abnormal QT cycle-length
relationship with failure of the QTc to shorten normally
with increasing heart rate and persistent prolongation in the
recovery stage have been reported in some subjects, espe-
cially those with LQT1 (93).
In the normal population, women have longer QT
intervals, probably due to QT shortening in men after
puberty, rather than QT prolongation in women during
reproductive years (94). In LQTS, men exhibit shorter
mean QTc values than both women and children (90,95),
for both genotype-positive and -negative blood relatives.
Thus, it has been postulated that adult gender differences in
the propensity toward torsade de pointes reflect the rela-
Table 2. Genotype-Specific Clinical Features*
LQT1 LQT2 LQT3
Arrhythmia onset Physical exercise Auditory stimuli Rest, sleep
T wave abnormality Prolonged T wave duration Small or notched T wave Delayed onset of T wave
Cardiac events through age of 40
$1 event (%)† 62 46 18
$2 event (%)† 37 36 5
Lethality of cardiac events (%)† 4 4 20
Median age at first event (yr)‡ 9 12 16
*Data are gathered from Vincent et al. (20), Zareba et al. (22), Ackerman (28), Wilde et al. (23), Schwartz et al. (88) and Locati et al. (90); †p , 0.001 for the comparison of
all three groups; ‡P , 0.05 for the comparison of all three groups.
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tively greater presence in men of a factor that blunts QT
prolongation responses (21).
QT dispersion. In addition to the temporal heterogeneity
described above (i.e., the ECG can sporadically be normal),
repolarization in LQTS also displays substantial spatial (96)
and transmural (97) heterogeneity. Spatial dispersion of QT
and QTc have been calculated using two indexes: the
difference between the longest and the shortest value mea-
sured in each of the 12 ECG leads (QTmax-QTmin,
QTcmax-QTcmin) and the relative dispersion of QT and
QTc (standard deviation of QT/QT average 3 100, stan-
dard deviation of QTc/QTc average 3 100). Both indexes
of dispersion of repolarization are increased in LQTS
patients compared with control subjects (96).
T-U wave abnormalities and T wave alternance. It has
been proposed that the degree of transmural heterogeneity
can be determined by the duration of the second half
(post-peak) of the T wave (97). Repolarization of the
epicardial action potential, the earliest to repolarize, was
found to coincide with the peak of the T wave in vitro;
repolarization of the midmyocardial cells (M cells), the last
to repolarize, coincided with the end of the T wave. Thus,
it was proposed that the action potential duration of the
longest M cells determines the QT interval and the Tpeak-
Tend interval serves as an index of transmural heterogeneity
of repolarization.
Patients with LQTS may present with multiple morpho-
logical abnormalities of T wave, such as broad-based,
biphasic, bifid or notched T waves. These T wave abnor-
malities can be observed in normal subjects but much less
commonly than in patients with LQTS (15% vs. 62%) (98).
Among LQTS patients, these T wave abnormalities were
more common in those with a history of cardiac arrest or
syncope (81% vs. 19%) (98). A notched T wave observed
during the recovery phase of exercise tests is reported to be
highly suggestive of LQTS (98).
Different patterns of the ST-T wave complex have also
been suggested in patients with LQTS (Fig. 2). T wave
duration is particularly long in patients with LQT1. Pa-
tients with LQT2 usually have small T and/or notched T
waves. T wave onset is unusually prolonged in patients with
LQT3 (99). In a preliminary report (100), genotypes were
correctly predicted in 98% of families with typical patterns.
Overall, 80% of families were correctly predicted based on
ECG ST-T wave pattern (100).
Temporal heterogeneity of the repolarization in LQTS
can also be observed in beat-to-beat alternation of T wave
polarity or amplitude (T wave alternans). It may be observed
briefly at rest but most commonly appears during emotional
or physical stress and may herald torsade de pointes and is
a marker for high-risk patients (5).
Bradycardia. Some reports suggest that the average resting
heart rate is lower in LQTS patients, especially in children,
compared with normal control subjects (6). In addition,
patients with LQTS have a mean heart rate lower than
normal controls during moderate and maximal exercise, but
there is considerable overlap with the normal distribution.
Sinus node dysfunction has been reported in patients with
LQTS (93). Some patients have sinus arrest and a notched
T wave in the first beat after a pause. Repetitive ventricular
beats and torsade de pointes usually take off from the second
peak after the notch (101). It has been reported that after
successful left cardiac sympathetic denervation, the notched
T wave will disappear after a pause (101). An especially
malignant form of LQTS presents with 2:1 atrioventricular
block and/or intraventricular conduction disturbances likely
arising because of very marked action potential prolongation
in the conducting system (102).
The extent of sinus bradycardia is highly variable, which
suggests that either certain gene defects are more likely to be
associated with this manifestation of the disease than others
or expression of other genes determines whether an indi-
vidual subject develops sinus bradycardia (21).
CARDIAC ARRHYTHMIAS
Monophasic action potential recordings have shown that
action potential durations are prolonged in ventricular
muscle in LQTS (97). Early afterdepolarizations are
thought to arise during prolonged phase 2 or phase 3 of the
action potential as a result of reactivation of L-type calcium
currents or possibly other inward currents, such as sodium-
calcium exchange current or sodium current (103). Typi-
cally, torsade de pointes starts with a premature ventricular
depolarization, followed by a compensatory pause. The next
sinus beat often has a markedly prolonged QT interval and
an even more bizarre T wave. This is then followed by a
train of polymorphic ventricular tachycardia (torsade de
pointes) (Fig. 3) (104) whose first beat may represent
triggering from an early afterdepolarization. The “short-
long-short” sequence heralding torsade de pointes is a
hallmark of LQTS. Torsade de pointes may stop sponta-
neously, accounting for syncopal attacks, or may degenerate
into ventricular fibrillation with sudden death as a terminal
event.
El-Sherif and his associates (105) found that by analysis
of tridimensional activation patterns in an animal model of
LQTS, the initial beat of polymorphic ventricular tachycar-
dia consistently arose as focal activity from a subendocardial
Figure 2. Different patterns of ST-T wave complex in patients with long
QT syndrome. Please see text for detail (adapted from reference [99] with
permission).
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site, whereas subsequent beats were due to successive sub-
endocardial focal activity, reentrant excitation or a combi-
nation of both mechanisms (105). They further showed that
an apparent shift in QRS axis in torsade de pointes was due
to a predominantly single localized circuit that varied its
location and orientation from beat to beat, with the majority
of ventricular myocardium being activated in a centrifugal
pattern (106). This suggests early afterdepolarization-
related initiation in the Purkinje system (subendocardium)
with maintenance by reentry.
DIAGNOSIS
A history of unexplained syncope or sudden death in a child
or young adult, especially during physical exertion or emo-
tional agitation, and a history of unexplained drowning or
near-drowning, should provoke a suspicion of the possibility
of LQTS (28,43). Seizure or syncope seemingly precipitated
by “fight, flight or fright” has been said to indicate LQTS
until proven otherwise (28). More than one half of the 8,000
sudden unexpected deaths in children may be attributable to
LQTS (28), and the 10-year mortality rate of untreated
LQTS may be as high as 50%, making consideration of the
diagnosis mandatory in some clinical situations. Despite
advances in the understanding of the molecular mechanisms
underlying the cellular electrophysiologic defects found in
patients with LQTS, the diagnosis is still based on the
clinical characteristics of the patient and the family. In those
with characteristic features of LQTS, the typical cases
present no diagnostic difficulty, assuming the physician is
aware of the disease. However, borderline cases are more
complex and require integration of multiple clinical vari-
ables including ECG findings at rest and with exercise,
clinical history and family history.
Schwartz et al. (7) proposed the first diagnostic criteria
for LQTS in 1985, providing a quantitative approach to the
diagnosis of LQTS by giving different weights to major and
minor criteria. Subsequent developments in understanding
LQTS, including the findings that women have longer QTc
than men, that there is a large overlap of QTc values
between gene carriers and noncarriers and that there are a
number of clinical parameters found to be significantly
different between patients with and without LQTS, led to
the formulation of new criteria published in 1993 (107).
These new criteria are shown in Table 3 (107). They are
based on findings from the ECG, clinical history and family
history. The point total ranges from 0 to 9. Three proba-
bility categories have been defined: ,1 point 5 low prob-
ability; 2 to 3 points 5 intermediate probability; .4
points 5 high probability. In patients with a score of 2 to 3
points, serial ECGs should be obtained since the QTc value
in patients with LQTS may vary from time to time.
Furthermore, screening ECGs from other family members
will be needed.
Exercise testing and Holter monitoring should be per-
formed on all suspected LQTS patients, although the
positive predictive accuracy is small. Corrected QT interval
shortening or lengthening during or after exercise testing
has not been very useful, because there are few normal
standards and prospective studies on the accuracy of these
QTc changes in risk stratification have not been performed.
Invasive electrophysiologic testing, with and without cate-
cholamine infusion, is not useful.
In borderline cases, genetic testing to identify new mu-
tations may eventually be used but has not yet matured to
Figure 3. The short-long-short sequence before the onset of torsade de pointes in a patient with long QT syndrome.
Table 3. Diagnostic Criteria in LQTS (107)
Points
Electrocardiographic findings*
QTc†
.480 ms 3
460–470 ms 2
450 (men) ms 1
Torsade de pointes‡ 2
T wave alternans 1
Notched T wave in three leads 1
Low heart rate for age§ 0.5
Clinical history
Syncope‡
With stress 2
Without stress 1
Congenital deafness 0.5
Family history\
Family members with definite LQTS¶ 1
Unexplained sudden cardiac death before
age 30 among immediate family
members
0.5
Scoring: , 1 point 5 low probability; 2 to 3 points 5 intermediate probability; .4
points 5 high probability.
*In the absence of medications or disorders known to affect these ECG features;
†QTc calculated by Bazett’s formula, where QTc 5 QT/=RR; ‡mutually exclusive;
§resting heart rate below the second percentile for age; \the same family member
cannot be counted twice; ¶definite LQTS is defined by an LQT score .4.
LQTS 5 long QT syndrome; QTc 5 corrected QT interval.
7JACC Vol. 36, No. 1, 2000 Chiang and Roden
July 2000:1–12 Long QT Syndrome
become a routinely available clinical tool. In a recent report
of nine families with sporadic cases of LQTS (26), that is,
families in which, besides the proband, none of the family
members had clinical signs of the disease, 33% of the 46
family members were found to be gene carriers by molecular
diagnosis, with an estimated penetrance of only 25%. It
seems appropriate to perform molecular screening in all
family members of genotyped patients, when available.
Contemporary molecular approaches can be used to
analyze genomic DNA (e.g., from peripheral lymphocytes)
and to detect LQTS-associated mutations. This approach is
particularly useful for members in a family in which the
causative mutant gene and specific mutations have been
identified from a proband. At least one case of mutations in
both HERG and KVLQT1 have been found in two severely
affected sisters from a large LQTS family (double heterozy-
gosity), suggesting that genetic analysis of severely affected
young patients should include an investigation for .1
mutation in the LQT genes (58). Otherwise, screening for
disease-associated mutations is not yet widely performed,
because it is costly and time-consuming and because some
unknown LQTS genes remained to be determined. The
genomic structure of all five known human LQTS genes is
now known, an important step in making presymptomatic
diagnosis for the mutations in these gene loci more widely
available (15,71,108).
MANAGEMENT
For asymptomatic patients there are differing opinions with
regard to the need for treatment. Schwartz et al. (109)
initially recommended treatment for patients without symp-
toms in six conditions:
1) in those with congenital deafness because the risk of
cardiac events is particularly high;
2) in neonates and infants because the risk is especially high
during the first months of life;
3) in affected siblings of children who have died suddenly,
because of the emotional stress present in the family;
4) in patients with documented T wave alternans because
this is a sign of enhanced electrical instability;
5) in patients with very long QTc (.600 ms), a group
thought to be more symptomatic;
6) when there is anxiety and an explicit request for treat-
ment in a family after thorough explanation.
Vincent et al. (20) and Garson et al. (92) have recom-
mended treatment for all asymptomatic patients if under age
40 at the time of diagnosis since it is sometimes impossible
to predict which asymptomatic patient will become symp-
tomatic, and 30% to 40% of sudden deaths occur at the first
event. In a recent analysis done by Priori et al. (110), death
as the first symptom was found to be common, suggesting
all young asymptomatic patients should be treated.
There is no disagreement that symptomatic patients need
treatment. There are five modalities of treatment for pa-
tients with LQTS at the present time: 1) beta-blockers, 2)
pacemakers, 3) left cardiac sympathetic denervation, 4)
implantable cardioverter-defibrillator, and 5) gene-based
therapy. The goal of therapy is to prevent malignant
ventricular tachyarrhythmias (ventricular tachycardia, tor-
sade de pointes and ventricular fibrillation).
Beta-blockers. Beta-blockers remain first-line treatment
for LQTS. Initially described in 1975 (6) and then substan-
tiated by the beneficial effect reported in 1985 (7), the
reported effect of beta-blocker therapy is to decrease mor-
tality from 71% in historical controls to 6% in a treated
group (109). Syncope or other events recur in patients on
beta-blockers in about 25% of cases, and the chance of
sudden death at five years has been estimated to be 10%
despite therapy (111).
The dose of beta-blockers should be maximized, ascer-
tained by a reduced heart rate response to treadmill exercise
testing, aiming for a maximal heart rate of 130 beats/min or
less. All beta-blockers appear to be effective, and no pro-
spective comparative studies have been performed. Propran-
olol is widely used, at a daily dose of 2 to 3 mg/kg. Nadolol
is also widely used because of its longer half-life (so missing
a dose may not be catastrophic). Noncompliance exposes
patients to their baseline risk of cardiac events and probably
accounts for a percentage of treatment failure, especially in
adolescents. In patients who develop severe bradycardia or
profound sinus arrest (e.g., .2.0 s), concomitant pacemaker
therapy is indicated.
The precise mechanism of the efficacy of beta-blockers in
LQTS remains unknown. The QTc remains prolonged
after effective treatment with beta-blockers, but QTc dis-
persion, measured as (QTc maximum minus QTc mini-
mum), decreases in the responders (112). A cutoff value of
100 ms for QTmax minus QTmin had an 80% sensitivity
and 82% specificity in discriminating between responders
and nonresponders. In one series, LQTS patients who did
not respond to beta-blockade underwent left cardiac sym-
pathetic denervation and, thereafter, remained asymptom-
atic (mean follow-up, 5 6 4 years). In this group, dispersion
of repolarization was significantly reduced by the surgical
denervation to values similar to that of the responders to
beta-blockade (112). Thus, the persistence of excessive QT
dispersion after the institution of therapy with beta-blockers
is one possible marker that may allow the early identification
of patients likely to remain at high risk and may, therefore,
suggest the need to proceed to alternate therapies.
Recently, Shimizu et al. (113) showed in a canine model
that chromanol 293B (an IKs blocker) was not sufficient to
induce torsade de pointes but that the addition of a
beta-agonist was highly arrhythmogenic, likely by increas-
ing transmural dispersion of repolarization. They postulated
that this was a result of a large augmentation of residual IKs
in epicardial and endocardial cells but not in M cells, in
which IKs is intrinsically less prominent. This study provides
a mechanistic understanding of the cellular basis for the
therapeutic actions of beta-blockers in LQT1. In a human
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study, Shimizu et al. (114) also demonstrated that the
addition of propranolol completely reversed the effect of
epinephrine in prolonging the QT interval and increasing
the dispersion in LQT1 patients. A possibly related mech-
anism for beta-blocker efficacy is inhibition of reactivated
inward calcium current, an effect that would apply to all
forms of LQTS. Verapamil, an L-type calcium channel
blocker, has been demonstrated to eliminate or reduce early
afterdepolarizations and suppress torsade de pointes in
patients with LQTS who underwent challenge with epi-
nephrine infusion (103). Verapamil may be an effective
alternative for patients unable to tolerate beta-blockers, such
as patients with asthma, although long-term safety and
efficacy data are not available.
Cardiac pacing. The beneficial effects of pacing in high-
risk LQTS patients probably relate to the prevention of
bradycardia and pauses and the shortening of long QT
interval, factors that are known to be arrhythmogenic (111).
However, pacemakers should not be regarded as a sole
therapy for LQTS and should be used as an adjunct to
beta-blockers to prevent the occurrence of severe bradycar-
dia, or pauses, in patients with pre-existing atrioventricular
block or when there is evidence of pause-dependent ar-
rhythmias.
Left cardiac sympathetic denervation. Left cardiac sym-
pathetic denervation should be reserved as a back-up ther-
apy when repeated syncopal attacks are not controlled by
beta-blockers and pacing. The largest series, reported by
Schwartz et al. (109), enrolled 123 patients and was claimed
to be representative because it encompassed 90% of the
entire LQTS population who underwent left cardiac sym-
pathetic denervation and had a long follow-up period
(mean 5 10 years). All these patients were unresponsive to
or did not tolerate the full-dose of beta-blockers. Left
cardiac sympathetic denervation produced a marked de-
crease in the number of patients with cardiac events (from
99% to 45%) and in the number of cardiac events per patient
(from 21 6 31 to 1 6 3). Most of the patients who still had
cardiac events after surgery had only one, usually during the
first six months. The total incidence of sudden death was
8% in 10 years, and the five-year survival rate was 94%.
In order to achieve adequate left cardiac sympathetic
denervation in humans, it is necessary to remove the first
four to five of the left thoracic ganglia together with the
lower half of the left stellate ganglion. Preservation of the
upper half of the left stellate ganglion will avoid iatrogenic
Horner’s syndrome.
Implantable cardioverter-defibrillator. An implantable
cardioverter-defibrillator is currently used when the combi-
nation of beta-blockers, left cardiac sympathetic denervation
and/or pacing fails to prevent the syncopal attacks. It is also
proposed as first-line therapy when the presenting event is a
resuscitated cardiac arrest. While the implantation of an
implantable cardioverter-defibrillator truly appears to de-
crease the incidence of sudden death in patients with LQTS
(115), implantable cardioverter-defibrillators can also pro-
duce emotional distress that can trigger arrhythmias and
shocks. To avoid shocks for episodes of short, self-
terminating torsade de pointes, a revised detection and
treatment algorithm has been incorporated into some de-
vices.
Gene-based therapy. In LQT3 patients, experimental
(116) and clinical studies (24) have suggested that the
sodium channel blockers, mexiletine and lidocaine, may
prevent the repetitive opening of the channel, shorten the
QT interval and normalize the morphology of the T wave.
Thus, they have been viewed as “gene-specific” LQT3
therapies. However, in both LQT2 and LQT3 models,
mexiletine has also been shown to be effective in reducing
dispersion and preventing torsade de pointes (117). As well,
in a canine model of LQT1, mexiletine abbreviated the
action potential duration of M cells more than that of
epicardium and endocardium, thus diminishing transmural
dispersion and the effect of isoproterenol to induce torsade
de pointes (113). Currently, these therapies can be regarded
only as adjuncts to beta-blockers, and their usefulness as sole
therapy for LQTS needs further studies. Importantly, QT
shortening cannot be equated with reduced risks. Thus,
while molecular genetic studies may raise the possibility of
genotype-specific therapies targeting ion channels, any in-
tervention that decreases net inward current or increases net
outward current will decrease QT interval and may protect
LQTS patients from arrhythmias. Increasing the patient’s
serum potassium level to about 1.5 mEq/L above baseline
with spironolactone, potassium chloride intravenous infu-
sion and oral potassium chloride supplementation resulted
in a 24% reduction in the QTc in seven patients with
LQT2, compared with 4% in five healthy control subjects,
and resolved the notched T wave abnormality (25). This is
thought to reflect increased IKr and should be effective in all
forms of LQTS. On the other hand, although raising serum
potassium reverses the ECG abnormalities in LQT2, a
long-lasting rise of serum potassium may be only partially
achievable because of normal renal function (118). Nicoran-
dil, an opener of the ATP-sensitive potassium channel, has
been shown to improve the repolarization abnormalities
during epinephrine infusion in LQT1 patients (114), and
nicorandil has been reported to be effective in a patient with
LQTS whose syncopal attacks were refractory to beta-
blockade (119). The long-term effect of potassium channel
openers in patients with LQTS needs to be determined.
FUTURE DIRECTIONS
The history of LQTS began with single cases and has
progressed to a firm understanding of basic genetic and
molecular mechanisms. There is now a prospect for specific
therapy, based on genotype and, conceivably, actual gene
therapy. Most importantly, the identification of LQTS
genes has provided tremendous new insights for our under-
standing of normal cardiac electrophysiology and its pertur-
bation in a wide range of conditions associated with sudden
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death. It seems likely that this paradigm, using new genetic
approaches in congenital and acquired diseases, will be an
increasingly important one in the next millennium.
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